Objective: To investigate the effects of chidamide combined with anti-myeloma drugs on the proliferation and apoptosis of myeloma cells.
Methods: The proliferation inhibition of the cells was detected by CCK-8 method, and flow cytometry was used to detected the apoptosis of the cells.
Results: Chidamide could inhibit the proliferation of myeloma cells and promote the apoptosis of primary myeloma plasma cells in a time- and dose-dependent manner (P<0.05). In NCI-H929 cell line, chidamide combined with low-dose bortezomib and lenalidomide showed synergistic effect, while combined with dexamethasone and pomalidomide showed additive effect. In MM.1s cell line, chidamide combined with bortezomib, dexamethasone, lenalidomide and pomalidomide all showed synergistic effects.
Conclusion: Chidamide inhibits proliferation of myeloma cells in a time- and dose-dependent manner and promotes apoptosis of primary myeloma plasma cells. Furthermore, it can enhance the inhibitory effect of anti-myeloma drugs.
题目: 西达苯胺联合抗骨髓瘤药物对骨髓瘤细胞的增殖及凋亡的影响.
目的: 探讨西达苯胺联合抗骨髓瘤药物对骨髓瘤细胞的增殖及凋亡的影响。.
方法: 用CCK-8法检测细胞的增殖抑制，流式细胞术检测细胞的凋亡变化。.
结果: 西达苯胺以时间、剂量依赖性方式抑制骨髓瘤细胞的增殖（NCI-H929，r=0.720；MM.1s，r=0.636），同时促进原代骨髓瘤浆细胞的凋亡。在NCI-H929细胞系上，西达苯胺联合低剂量硼替佐米、来那度胺具有协同作用，联合地塞米松、泊马度胺具有相加作用；在MM.1s细胞系上，西达苯胺联合硼替佐米、地塞米松、来那度胺、泊马度胺均具有协同作用。.
结论: 西达苯胺以时间、剂量依赖方式抑制骨髓瘤细胞的增殖，促进原代骨髓瘤浆细胞的凋亡，并增强抗骨髓瘤药物的抑制作用。.